AtaiBeckley ATAI
NASDAQ ATAI
$7.34 -0.01 (-0.07%)
As of: Sep 4, 2026 · 1:39 PM EDT

AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026)

AtaiBeckley (ATAI) posted Net Income towards Common Stockholders of -$61.1 million for Q3 2025, down 120.25% sequentially from -$27.7 million in Q2 2025, and down 132.34% YoY from $188.8 million in Q3 2024.

Analysis

AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

AtaiBeckley's Net Income towards Common Stockholders history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 12.68% year-over-year to -$29.8 million; the TTM figure through Mar 2026 stood at -$56.2 million (changed N/A YoY), while the FY2025 annual figure was -$659.9 million, down 344.64% from the prior year.
  • Net Income towards Common Stockholders slipped to -$61.1 million in Q3 2025 per ATAI's latest filing, from -$27.7 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$26.4 million in Q1 2025, with the low at -$29.8 million in Q1 2026.
  • A 5-year average of -$30.3 million and a median of -$33.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slumped 741.53% in 2022, then jumped 230.56% in 2023.
  • Over 5 years, Net Income towards Common Stockholders stood at -$49.3 million in 2021, then increased by 18.3% to -$40.3 million in 2022, then soared by 53.45% to -$18.7 million in 2023, then plunged by 107.97% to -$39.0 million in 2024, then sank by 56.64% to -$61.1 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$61.1 million, -$27.7 million, and -$26.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 472.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 81.49 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn -13.27 Mn
10 AtaiBeckley 1.60 Bn 1.60 Bn - -61.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.52 Mn
Mar 31, 2026 -29.78 Mn
Sep 30, 2025 -61.07 Mn
Jun 30, 2025 -27.73 Mn
Jun 30, 2025 -27.73 Mn
Mar 31, 2025 -26.43 Mn
Mar 31, 2025 -26.43 Mn
Dec 31, 2024 -38.63 Mn
Sep 30, 2024 -26.29 Mn
Jun 30, 2024 -57.31 Mn
Mar 31, 2024 -26.71 Mn
Dec 31, 2023 -18.74 Mn
Sep 30, 2023 44.24 Mn
Jun 30, 2023 -33.04 Mn
Mar 31, 2023 -33.14 Mn
Dec 31, 2022 -45.32 Mn
Sep 30, 2022 -33.89 Mn
Jun 30, 2022 -36.62 Mn
Mar 31, 2022 -36.87 Mn
Dec 31, 2021 -52.14 Mn